Novamycin® (NP339) is a novel antifungal peptide developed for front-line treatment of medically unmet, yeast and mould infections, particularly those caused by Aspergillus spp. and Candida spp.
Mortality rates for Aspergillus infections are as high as 80% (100% without treatment) and Candida remains the most common cause (over 50%) of hospital based (nosocomial) blood stream or deep tissue fungal infections. Invasive fungal disease (IFD), caused by these and other fungal pathogens, is a growing medical problem associated with a failure or inability of the body's immune system to fight off opportunistic fungi.
Clinical and Commercial Development
Novamycin is unique as the first antifungal in development for the treatment of fungal disease as an inhaled, systemic and mucocutaneous therapy. NP339 is a rapidly acting fungicidal peptide that has demonstrated superiority over existing antifungal classes in preclinical testing (with a placebo like safety profile) for a number of fungal infections. Novamycin is currently in an IND enabling toxicology programme ahead of entering the clinical development stage.
Novamycin acts through membrane perturbation and lysis; this mode of action rapidly killing both non-metabolising and metabolically active fungi. This mechanism of action minimises or negates the risk of acquired drug resistance. Novamycin has been shown to be active against pathogens that are resistant/insensitive to conventional antifungals and has a placebo-like safety profile.
AB21 9TR, UK
Tel: +44 (0)1224 711377
9121 Anson Way,
North Carolina 27615, US